Multi-omics analysis and experiments uncover the link between cancer intrinsic drivers, stemness, and immunotherapy in ovarian cancer with validation in a pan-cancer census.

Journal: Frontiers in immunology
Published Date:

Abstract

BACKGROUND: Although immune checkpoint inhibitors (ICIs) represent a substantial breakthrough in cancer treatment, it is crucial to acknowledge that their efficacy is limited to a subset of patients. The heterogeneity and stemness of cancer render its response to immunotherapy variable, warranting the identification of robust biomarkers for evaluation.

Authors

  • Yilin Li
    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Cen Chen
  • Xiaoyu Ji
    Department of Oncology, Huashan Hospital Fudan University, Shanghai, China.
  • Ningxiao Jiang
    Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, Shandong, China.
  • Fei Wang
    Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, United States.
  • Xiangqian Gao
    Department of Pathology, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, Shandong, China.
  • Weiwei Chen
    Department of Developmental and Behavioral Pediatrics, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine, Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Shanghai, China.
  • Qiang Tang
    Center of Bioinformatics (COBI), Key Laboratory for NeuroInformation of Ministry of Education, University of Electronic Science and Technology of China, Chengdu 610054, China.
  • Yan Li
    Interdisciplinary Research Center for Biology and Chemistry, Liaoning Normal University, Dalian, China.
  • Shinan Zhang
    Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou Medical University, Binzhou, Shandong, China.
  • Gaofeng Qin
    Department of Traditional Chinese Medicine, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Yingjiang Xu
    Department of Interventional Vascular Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Yanlin Wang
    Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
  • Lingwen Kong
    Institute of Intergrated Traditional Chinese and Western Medicine, Huashan Hospital Fudan University, Shanghai, China.
  • Lei Han
    Jiangsu Province Center for Disease Prevention and Control, Institute of Occupational Disease Prevention, Nanjing, Jiangsu, China.
  • Jie Mei
    Department of Neurology and Department of Experimental Neurology, Neurocure Cluster of Excellence, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.